Ceftazidime/avibactam as a possible treatment option for carbapenem-resistant Enterobacterales infections
Carbapenem resistance (CR) in Enterobacterales is frequently determined by the production of enzymes, so called carbapenemases, (KPC, NDM, OXA-48 etc) or by porin deficiencies, combined with ESBLs. Several new agents with activity against certain carbapenemresistant pathogens have been approved for...
Saved in:
Main Authors: | Ana Kaftandzieva, Gordana Mirchevska |
---|---|
Format: | Article |
Language: | English |
Published: |
University Ss Cyril and Methodius in Skopje, Faculty of Pharmacy and Macedonian Pharmaceutical Association
2025-12-01
|
Series: | Makedonsko Farmacevtski Bilten |
Subjects: | |
Online Access: | http://bulletin.mfd.org.mk/volumes/Volume%2071_2/71_2_004.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals
by: Lalitagauri M Deshpande, et al.
Published: (2025-09-01) -
Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01) -
Mortality of metallo-β-lactamase-producing Enterobacterales bacteremias with combined ceftazidime–avibactam plus aztreonam vs. other active antibiotics: a multicenter target trial emulationResearch in context
by: Ivan Alfredo Huespe, et al.
Published: (2025-09-01) -
Mortality and clinical outcomes of ceftazidime/avibactam vs best available therapy in treating carbapenem-resistant enterobacterales infections: A retrospective cohort study
by: Nada Alhamed, et al.
Published: (2025-07-01) -
Clinical Efficacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria
by: S. V. Yakovlev
Published: (2021-10-01)